Fundraising Fox
Perfuse Therapeutics
San Francisco, US · Founded 2018 · Delaware corporation · 9 employees on LinkedIn · 7 known investors
Find your way into Perfuse Therapeutics
Sign up to see every warm intro you have to Perfuse Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Perfuse Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms. The company focuses on advancing therapeutic programs from preclinical development through clinical stages.
Founders & leadership
Perfuse Therapeutics was founded in 2018 by Sevgi Gurkan.
Board
Investors · 7
How we know: OrbiMed's portfolio page · the company's own site · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: Hatteras Venture Partners's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$11M disclosed across 2 rounds · 2019–2020
▶$9MraisedJul 2020 · 8 investors · BiotechnologyRule 506(b)
- Hongbo LuDirector
- Christy ShafferDirector
- Chau KhuongDirector
- Sevgi GurkanExecutive Officer, Director, Promoter
- Dan BeckerDirector
- Jerry CagleDirector
- Offering amount
- $39M
- Amount sold
- $9M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$2MraisedApr 2019 · 6 investors · Other TechnologyRule 506(b)
- Christy ShafferDirector
- Chau KhuongDirector
- Sevgi GurkanExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Perfuse Therapeutics.
Frequently asked questions
- What does Perfuse Therapeutics do?
- Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms. The company focuses on advancing therapeutic programs from preclinical development through clinical stages.
- Who founded Perfuse Therapeutics?
- Perfuse Therapeutics was founded by Sevgi Gurkan in 2018.
- Who are Perfuse Therapeutics's investors?
- Perfuse Therapeutics's investors include OrbiMed, Access Biotechnology, Catalio Capital Management, LP, Hatteras Venture Partners, LAV, Lilly Asia Ventures, Hatteras.
- How much funding has Perfuse Therapeutics raised?
- Perfuse Therapeutics has disclosed $11M raised across 2 rounds.
- Where is Perfuse Therapeutics headquartered?
- Perfuse Therapeutics is headquartered in San Francisco, US.